IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics
GET POWR RATINGS... FREE!
IGMS Stock Price Chart Interactive Chart >
IGMS Price/Volume Stats
| Current price | $16.56 | 52-week high | $99.44 |
| Prev. close | $16.32 | 52-week low | $12.74 |
| Day low | $15.90 | Volume | 233,600 |
| Day high | $17.03 | Avg. volume | 875,647 |
| 50-day MA | $18.56 | Dividend yield | N/A |
| 200-day MA | $37.64 | Market Cap | 704.25M |
IGM BIOSCIENCES, INC. (IGMS) Company Bio
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
Latest IGMS News From Around the Web
Below are the latest news stories about IGM Biosciences Inc that investors may wish to consider to help them evaluate IGMS as an investment opportunity.
IGM Biosciences: Interesting Science, Poor Trial DataNo summary available. |
Why Did IGM Biosciences Shares Advance Today?IGM Biosciences Inc (NASDAQ: IGMS ) has progressed two Phase 1 trials evaluating IGM-6268 , an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent infection COVID-19. The first Phase 1 trial is a single (SAD) and multiple (MAD) ascending dose study to assess Full story available on Benzinga.com |
IGM Biosciences updates on early-stage studies for intranasal COVID-19 therapyIGM Biosciences (IGMS) announced upcoming milestones for the company’s early-stage trials for IGM-6268, an investigational monoclonal antibody, being developed as a treatment or… |
IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – |
IGM Biosciences to Present at the Guggenheim 2022 Oncology ConferenceMOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Guggenheim 2022 Oncology Conference on Thursday, February 10, 2022 at 1:00 p.m. EST. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’ |
IGMS Price Returns
| 1-mo | -7.07% |
| 3-mo | 2.22% |
| 6-mo | -65.77% |
| 1-year | -77.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -43.54% |
| 2021 | -66.78% |
| 2020 | 131.37% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...